Infection as a comorbidity of COPD

European Respiratory Journal

Volumn 35, Issue 6, 2010, Pages 1209-1215

  Sethi, S ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Chronic obstructive pulmonary disease; Community acquired pneumonia; HIV; Infection

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; BACTERIAL DNA; BECLOMETASONE; BUDESONIDE PLUS FORMOTEROL; CEPHALOSPORIN; CHEMOKINE; CORTICOSTEROID; COTRIMOXAZOLE; CYTOKINE; ENDOTOXIN; FLUTICASONE; FLUTICASONE PROPIONATE PLUS SALMETEROL; GELATINASE B; INTERLEUKIN 8; MACROLIDE; PROTEINASE; PROTEINASE INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SALMETEROL; TETRACYCLINE;

ADENOVIRUS INFECTION; AIRWAY OBSTRUCTION; ANTIBIOTIC THERAPY; ATTRIBUTABLE RISK; BACTERIAL COLONIZATION; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIUM CULTURE; BACTERIUM ISOLATION; BRONCHUS BIOPSY; BRONCHUS MUCOSA; CAUSE OF DEATH; CELL COUNT; CHLAMYDOPHILA PNEUMONIAE; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CILIARY MOTILITY; COHORT ANALYSIS; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; CYTOKINE PRODUCTION; DEFENSE MECHANISM; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; DOSE RESPONSE; DYSPNEA; ENTEROBACTERIACEAE; EXPOSURE; FLUORESCENCE IN SITU HYBRIDIZATION; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS PARAINFLUENZAE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEART DISEASE; HOST PATHOGEN INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOFLUORESCENCE MICROSCOPY; INCIDENCE; LONGITUDINAL STUDY; LOWER RESPIRATORY TRACT INFECTION; LUNG CLEARANCE; LUNG FUNCTION; LUNG LAVAGE; LUNG PARENCHYMA; MICROBIAL COLONIZATION; MIXED INFECTION; MOLECULAR TYPING; MORAXELLA CATARRHALIS; MORBIDITY; MORTALITY; MYCOPLASMA PNEUMONIAE; NEUTROPHIL; NEUTROPHILIA; OUTCOME ASSESSMENT; PNEUMOCYSTIS; PNEUMONIA; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; QUALITY OF LIFE; RECURRENT INFECTION; RESPIRATORY EPITHELIUM; REVIEW; RISK FACTOR; SENESCENCE; SMOKING; SMOKING CESSATION; SPUTUM ANALYSIS; STAPHYLOCOCCUS AUREUS; STRATIFICATION; STREPTOCOCCUS PNEUMONIAE; TRACHEOBRONCHIAL TREE; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION; VIRUS VIRULENCE;

ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; COMORBIDITY; HIV INFECTIONS; HUMANS; PNEUMONIA; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS; STEROIDS;

EID: 77953519935     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00081409     Document Type: Review

References (52)

1. Sethi S, Murphy TF. Bacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the-art review. Clin Microbiol Rev 2001; 14: 336-363.
2. Mannino DM, Homa DM, Akinbami LJ, et al. Chronic obstructive pulmonary disease surveillance - United States, 1971-2000. MMWR Surveill Summ 2002; 51: 1-16.
3. Andersson F, Borg S, Jansson SA, et al. The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respir Med 2002; 96: 700-708.
4. Gump DW, Phillips CA, Forsyth BR, et al. Role of infection in chronic bronchitis. Am Rev Respir Dis 1976; 113: 465-474.
5. McHardy VU, Inglis JM, Calder MA, et al. A study of infective and other factors in exacerbations of chronic bronchitis. Br J Dis Chest 1980; 74: 228-238.
6. Smith CB, Golden C, Klauber MR, et al. Interactions between viruses and bacteria in patients with chronic bronchitis. J Infect Dis 1976; 134: 552-561. (Pubitemid 8015072)
7. Fagon JY, Chastre J. Severe exacerbations of COPD patients: the role of pulmonary infections. Semin Respir Infect 1996; 11: 109-118. (Pubitemid 26184191)
8. Tager I, Speizer FE. Role of infection in chronic bronchitis. N Engl J Med 1975; 292: 563-571.
9. Sethi S, Evans N, Grant BJ, et al. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002; 347: 465-471. (Pubitemid 34879333)
10. Gompertz S, O'Brien C, Bayley DL, et al. Changes in bronchial inflammation during acute exacerbations of chronic bronchitis. Eur Respir J 2001; 17: 1112-1119.
11. Stockley RA, O'Brien C, Pye A, et al. Relationship of sputum colour to nature and outpatient management of acute exacerbations of COPD. Chest 2000; 117: 1638-1645. (Pubitemid 30413357)
12. Veeramachaneni SB, Sethi S. Pathogenesis of bacterial exacerbations of COPD. COPD 2006; 3: 109-115.
13. Murphy TF, Brauer AL, Sethi S, et al. Haemophilus haemolyticus: a human respiratory tract commensal to be distinguished from Haemophilus influenzae. J Infect Dis 2007; 195: 81-89.
14. Murphy TF, Brauer AL, Eschberger K, et al. Pseudomonas aeruginosa in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 177: 853-860.
15. Sethi S, Wrona C, Eschberger K, et al. Inflammatory profile of new bacterial strain exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 177: 491-497.
16. White AJ, Gompertz S, Bayley DL, et al. Resolution of bronchial inflammation is related to bacterial eradication following treatment of exacerbations of chronic bronchitis. Thorax 2003; 58: 680-685.
17. Sethi S, Sethi R, Eschberger K, et al. Airway bacterial concentrations and exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 176: 356-361.
18. Wilkinson TM. Host pathogen interaction during COPD exacerbations: moving on from microbiology by numbers? Am J Respir Crit Care Med 2007; 176: 323-325.
19. Sethi S, Muscarella K, Evans N, et al. Airway inflammation and etiology of acute exacerbations of chronic bronchitis. Chest 2000; 118: 1557-1565. (Pubitemid 32001777)
20. Hill AT, Campbell EJ, Hill SL, et al. Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. Am J Med 2000; 109: 288-295.
21. Chapman AJ Jr, Musher DM, Jonsson S, et al. Development of bactericidal antibody during Branhamella catarrhalis infection. J Infect Dis 1985; 151: 878-882. (Pubitemid 15094606)
22. Faden H, Bernstein J, Brodsky L, et al. Otitis media in children. I. The systemic immune response to nontypable Hemophilus influenzae. J Infect Dis 1989; 160: 999-1004.
23. Yi K, Sethi S, Murphy TF. Human immune response to nontypeable Haemophilus influenzae in chronic bronchitis. J Infect Dis 1997; 176: 1247-1252. (Pubitemid 27460990)
24. Wilkinson TM, Hurst JR, Perera WR, et al. Effect of interactions between lower airway bacterial and rhinoviral infection in exacerbations of COPD. Chest 2006; 129: 317-324.
25. Papi A, Bellettato CM, Braccioni F, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med 2006; 173: 1114-1121. (Pubitemid 43726892)
26. Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 2355-2365.
27. Ram FS, Rodriguez-Roisin R, Granados-Navarrete A, et al. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006; 2: CD004403.
28. Roede BM, Bresser P, Bindels PJ, et al. Antibiotic treatment is associated with reduced risk of a subsequent exacerbation in obstructive lung disease: an historical population based cohort study. Thorax 2008; 63: 968-973.
29. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. www.goldcopd.org/ GuidelinesResources.asp?l1=2&l2=0: Date last updated: 2007. Date last accessed: January 2008.
30. Pneumonia and influenza death rates: United States; 1979-1994. MMWR Morb Mortal Wkly Rep 1995; 44: 535-537.
31. Ginesu F, Pirina P. Etiology and risk factors of adult pneumonia. J Chemother 1995; 7: 277-285.
32. Almirall J, Gonzalez CA, Balanzo X, et al. Proportion of community-acquired pneumonia cases attributable to tobacco smoking. Chest 1999; 116: 375-379.
33. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone proprionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-789.
34. Nannini L, Cates CJ, Lasserson TJ, et al. Combined corticosteroid and long-acting b-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2007; 4: CD003794.
35. Rello J, Rodriguez A, Torres A, et al. Implications of COPD in patients admitted to the intensive care unit by community-acquired pneumonia. Eur Respir J 2006; 27: 1210-1216.
36. Restrepo MI, Mortensen EM, Pugh JA, et al. COPD is associated with increased mortality in patients with community-acquired pneumonia. Eur Respir J 2006; 28: 346-351.
37. Ruiz De Ona JM, Gomez Fernandez M, Celdran J, et al. [Pneumonia in the patient with chronic obstructive pulmonary disease. Levels of severity and risk classification.] Arch Bronconeumol 2003; 39: 101-105.
38. Garcia-Vidal C, Calbo E, Pascual V, et al. Effects of systemic steroids in patients with severe community-acquired pneumonia. Eur Respir J 2007; 30: 951-956.
39. American Thoracic Society/European Respiratory Society. Standards for the Diagnosis and Management of Patients with COPD. www.thoracic.org/sections/copd/ resources/copddoc.pdf Date last updated: 2004. Date last accessed: July 30, 2009.
40. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 2645-2653.
41. Laurenzi GA, Potter RT, Kass EH. Bacteriologic flora of the lower respiratory tract. N Engl J Med 1961; 265: 1273-1278.
42. Bandi V, Apicella MA, Mason E, et al. Nontypeable Haemophilus influenzae in the lower respiratory tract of patients with chronic bronchitis. Am J Respir Crit Care Med 2001; 164: 2114-2119. (Pubitemid 34020254)
43. Murphy TF, Brauer AL, Schiffmacher AT, et al. Persistent colonization by Haemophilus influenzae in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170: 266-272. (Pubitemid 38971411)
44. Sethi S, Maloney J, Grove L, et al. Airway inflammation and bronchial bacterial colonization in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 173: 991-998.
45. Banerjee D, Khair OA, Honeybourne D. Impact of sputum bacteria on airway inflammation and health status in clinical stable COPD. Eur Respir J 2004; 23: 685-691.
46. Soler N, Ewig S, Torres A, et al. Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease. Eur Respir J 1999; 14: 1015-1022.
47. Vitalis TZ, Kern I, Croome A, et al. The effect of latent adenovirus 5 infection on cigarette smoke-induced lung inflammation. Eur Respir J 1998; 11: 664-669. (Pubitemid 28194860)
48. Wilkinson TM, Patel IS, Wilks M, et al. Airway bacterial load and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003; 167: 1090-1095.
49. Black P, Staykova T, Chacko E, et al. Prophylactic antibiotic therapy for chronic bronchitis. Cochrane Database Syst Rev 2003; 1: CD004105.
50. Crothers K. Chronic obstructive pulmonary disease in patients who have HIV infection. Clin Chest Med 2007; 28: 575-587.
51. Morris A, Sciurba FC, Lebedeva IP, et al. Association of chronic obstructive pulmonary disease severity and Pneumocystis colonization. Am J Respir Crit Care Med 2004; 170: 408-413.
52. Diaz PT, King MA, Pacht ER, et al. Increased susceptibility to pulmonary emphysema among HIV-seropositive smokers. Ann Intern Med 2000; 132: 369-372.